Skip to main content
Erschienen in: Medical Oncology 1/2011

01.03.2011 | Original Paper

Osteolytic lesions marker in multiple myeloma

verfasst von: Irena Djunic, Ivo Elezovic, Milica Marinkovic, Nada Suvajdzic-Vukovic, Dragica Tomin, Gradimir Jankovic, Jelena Bila, Darko Antic, Ana Vidovic, Borka Neskovic, Dragica Nikolic-Vukosavljevic

Erschienen in: Medical Oncology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The degradation product of collagen type I carboxy terminal telopeptide (ICTP) represents a new biochemical parameter that reflects the changes in the resorption properties of skeletal system. Affection of the skeleton is one of the most important characteristics of multiple myeloma (MM). We estimated significance of ICTP as osteolysis predictor and overall survival in comparison with standard prognostic parameters β2-microglobulin and C-reactive protein (CRP), in patients with MM. With our results, we have shown significant difference in serum level of ICTP (P = 0.009) between patients with and without osteolysis on conventional radiography. It was proved that ICTP is the most significant predictor of osteolysis (P = 0.09), while CRP is the most significant risk factor for overall survival (P < 0.01). Being highly significant predictor of osteolysis, ICTP can be used for identification of patients with MM who had increased risk for developing osteolytic lesions.
Literatur
1.
Zurück zum Zitat Kyle RA. Multiple myeloma, review of 869 cases. Mayo Clin Proc. 1975;50:29–40.PubMed Kyle RA. Multiple myeloma, review of 869 cases. Mayo Clin Proc. 1975;50:29–40.PubMed
2.
Zurück zum Zitat Abilgard N, Brixen K, Eriksen EF, Kristensen JE, Nilsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica. 2004;89:567–77. Abilgard N, Brixen K, Eriksen EF, Kristensen JE, Nilsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica. 2004;89:567–77.
3.
Zurück zum Zitat Jakob C, Zavirski I, Heider U, et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res. 2003;9:3047–51.PubMed Jakob C, Zavirski I, Heider U, et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res. 2003;9:3047–51.PubMed
4.
Zurück zum Zitat Dimopoulos MA, Moulopoulos LA, Datseris I, et al. Imaging of myeloma bone disease-implications for staging, prognosis and follow-up. Acta Oncol. 2000;39:823–7.PubMedCrossRef Dimopoulos MA, Moulopoulos LA, Datseris I, et al. Imaging of myeloma bone disease-implications for staging, prognosis and follow-up. Acta Oncol. 2000;39:823–7.PubMedCrossRef
5.
Zurück zum Zitat Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol. 1999;104:723–9.PubMedCrossRef Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol. 1999;104:723–9.PubMedCrossRef
6.
Zurück zum Zitat Moulopoulos LA, Dimopoulos MA. Magnetic resonance imging of bone marrow in hematologic malignancis. Blood. 1997;90:2127–47.PubMed Moulopoulos LA, Dimopoulos MA. Magnetic resonance imging of bone marrow in hematologic malignancis. Blood. 1997;90:2127–47.PubMed
7.
Zurück zum Zitat Abilgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol. 2000;64:124–9. Abilgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol. 2000;64:124–9.
8.
Zurück zum Zitat Abilgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: eleveted pretreatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haem. 2003;120:235–42.CrossRef Abilgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: eleveted pretreatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haem. 2003;120:235–42.CrossRef
9.
Zurück zum Zitat Batallie R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event of pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62–6.CrossRef Batallie R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event of pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62–6.CrossRef
10.
Zurück zum Zitat Batallie R, Chappard D, Marcelli C, et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol. 1990;76:484–7.CrossRef Batallie R, Chappard D, Marcelli C, et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol. 1990;76:484–7.CrossRef
11.
Zurück zum Zitat Dizdar O, Barista I, Umut K, et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Haemat. 2007;82:185–91.CrossRef Dizdar O, Barista I, Umut K, et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Haemat. 2007;82:185–91.CrossRef
12.
Zurück zum Zitat Abilgaard N, Bentzen S, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haem. 1997;96:103–10.CrossRef Abilgaard N, Bentzen S, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haem. 1997;96:103–10.CrossRef
13.
Zurück zum Zitat Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem. 1997;30:573–93.PubMedCrossRef Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem. 1997;30:573–93.PubMedCrossRef
14.
Zurück zum Zitat Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (Ntx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol. 2002;69:37–42.PubMedCrossRef Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (Ntx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol. 2002;69:37–42.PubMedCrossRef
15.
Zurück zum Zitat Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin rations. Eur J Haematol. 1999;62(5):300–6.PubMedCrossRef Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin rations. Eur J Haematol. 1999;62(5):300–6.PubMedCrossRef
16.
Zurück zum Zitat Risteli J, Elomas I, Nieml S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone degradation. Clin Chem. 1993;39(4):635–40.PubMed Risteli J, Elomas I, Nieml S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone degradation. Clin Chem. 1993;39(4):635–40.PubMed
17.
Zurück zum Zitat Elmoaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992;66(2):337–41.CrossRef Elmoaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992;66(2):337–41.CrossRef
18.
Zurück zum Zitat Fonseca R, Trendle MC, Leong T, et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol. 2000;109:24–9.PubMedCrossRef Fonseca R, Trendle MC, Leong T, et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol. 2000;109:24–9.PubMedCrossRef
19.
Zurück zum Zitat Batallie R, Boccadoro M, Klein B, Durie BG, Pileri A. C-reactive protein and β2-microglobulin produce a simple and powerful myeloma staging sistem. Blood. 1992;80:733–7. Batallie R, Boccadoro M, Klein B, Durie BG, Pileri A. C-reactive protein and β2-microglobulin produce a simple and powerful myeloma staging sistem. Blood. 1992;80:733–7.
Metadaten
Titel
Osteolytic lesions marker in multiple myeloma
verfasst von
Irena Djunic
Ivo Elezovic
Milica Marinkovic
Nada Suvajdzic-Vukovic
Dragica Tomin
Gradimir Jankovic
Jelena Bila
Darko Antic
Ana Vidovic
Borka Neskovic
Dragica Nikolic-Vukosavljevic
Publikationsdatum
01.03.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9432-4

Weitere Artikel der Ausgabe 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.